2 research outputs found
The clinical evolution and dynamics of laboratory indices in HIV/AIDS infected patients who are treated with first-line antiretroviral therapy
Department of Infectious Diseases, Parasitology and Tropical Medicine, Nicolae Testemitsanu State University of Medicine and Pharmacy, National Center of Public Health, Republic of MoldovaThe clinical, immunological, virological and epidemiological data obtained from 48 adult patients diagnosed with HIV/AIDS infection have been
estimated. The late diagnostics is defined by the presence of AIDS associated diseases and/or the level of T-lymphocytes CD4 < 350 cells/ΞΌl. More than
half (66.67%) of the investigated patients showed severe immunity suppression and/or clinical AIDS associated diseases. The most frequent AIDS related
diseases were tuberculosis, oropharynx candidiasis, HIV depletion, Herpes Zoster, HIV encephalopathy and Kaposiβs sarcoma. The effectiveness of the
applied antiretroviral therapy (ART) schemes appreciated in terms of virological response is higher for the scheme Tenofovir+Emtricitabin+Efavirenz, and
in terms of immunologic response it is higher for the second scheme Zidovudin+Lamivudin+Nevirapin. The dissociated virological and immunological
response to highly active antiretroviral therapy (HAART) registered for some of the patients is in many cases the result of insufficient susceptibility to
the treatment, which increases the risk of the progression of the disease.
ΠΡΠ΅Π½Π΅Π½Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅, ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅, Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ ΡΠΏΠΈΠ΄Π΅ΠΌΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π΄Π°Π½Π½ΡΠ΅ 48 Π²Π·ΡΠΎΡΠ»ΡΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠΠ§/Π‘ΠΠΠ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ. ΠΠΎΠ·Π΄Π½ΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅ΡΡΡ Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ Π‘ΠΠΠβΠ°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΠΈ/ΠΈΠ»ΠΈ ΡΡΠΎΠ²Π΅Π½Π΅ΠΌ Π’-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² CD4 < 350 ΠΊΠ»/ΞΌΠ». Π£
Π±ΠΎΠ»Π΅Π΅ ΠΏΠΎΠ»ΠΎΠ²ΠΈΠ½Ρ (66,67%) ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΎ Π½Π°Π»ΠΈΡΠΈΠ΅ ΡΡΠΆΠ΅Π»ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡΠ½ΠΎΠ΄Π΅ΡΠΈΡΠΈΡΠ° ΠΈ/ΠΈΠ»ΠΈ Π‘ΠΠΠβΠ°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ. ΠΠ°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΠΌΠΈ Π‘ΠΠΠβΠ°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ Π±ΡΠ»ΠΈ ΡΡΠ±Π΅ΡΠΊΡΠ»Π΅Π·, ΠΊΠ°Π½Π΄ΠΈΠ΄ΠΎΠ· ΡΠΎΡΠΎΠ³Π»ΠΎΡΠΊΠΈ, ΠΠΠ§ ΠΈΡΡΠΎΡΠ΅Π½ΠΈΠ΅,
oΠΏΠΎΡΡΡΠ²Π°ΡΡΠΈΠΉ Π³Π΅ΡΠΏΠ΅Ρ, ΠΠΠ§-ΡΠ½ΡΠ΅ΡΠ°Π»ΠΎΠΏΠ°ΡΠΈΡ ΠΈ ΡΠ°ΡΠΊΠΎΠΌΠ° ΠΠ°ΠΏΠΎΡΠΈ. ΠΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΡΠΈΠΌΠ΅Π½ΡΡΡΠΈΡ
ΡΡ ΡΡ
Π΅ΠΌ Π²ΡΡΠΎΠΊΠΎΠ°ΠΊΡΠΈΠ²Π½ΠΎΠΉ Π°Π½ΡΠΈΡΠ΅ΡΡΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ
ΡΠ΅ΡΠ°ΠΏΠΈΠΈ (ΠΠΠΠ Π’) Ρ ΡΠΎΡΠΊΠΈ Π·ΡΠ΅Π½ΠΈΡ Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° ΠΎΠΊΠ°Π·Π°Π»Π°ΡΡ Π²ΡΡΠ΅ Π΄Π»Ρ ΡΡ
Π΅ΠΌΡ Tenofovir+Emtricitabin+Efavirenz, Π° Ρ ΡΠΎΡΠΊΠΈ Π·ΡΠ΅Π½ΠΈΡ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ²Π΅ΡΠ° ΠΎΠ½Π° ΠΎΠΊΠ°Π·Π°Π»Π°ΡΡ Π²ΡΡΠ΅ Π΄Π»Ρ ΡΡ
Π΅ΠΌΡ Zidovudin+Lamivudin+Nevirapin. ΠΠΈΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ Π²ΠΈΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΎΡΠ²Π΅Ρ Π½Π° ΠΠΠΠ Π’, Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ Ρ Π½Π΅ΠΊΠΎΡΠΎΡΡΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
, Π²ΠΎ ΠΌΠ½ΠΎΠ³ΠΈΡ
ΡΠ»ΡΡΠ°ΡΡ
ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠΌ ΠΏΠ»ΠΎΡ
ΠΎΠΉ Π²ΠΎΡΠΏΡΠΈΠΈΠΌΡΠΈΠ²ΠΎΡΡΠΈ
ΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠ° ΠΊ Π»Π΅ΡΠ΅Π½ΠΈΡ, ΡΡΠΎ ΠΏΠΎΠ²ΡΡΠ°Π΅Ρ ΡΠΈΡΠΊ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ